Matt Killeen , Ph.D.

President

Matt is the President of TikkunLev Therapeutics and has deep operational experience spanning precision therapy R&D, cardiovascular therapeutic development, portfolio strategy, and commercialization at companies including BioMarin, Biogen, and Renovacor.

At BioMarin, Matt founded the Cardiovascular Therapeutic Area and built a robust portfolio of next-generation pipeline programs, many of which were among the first gene and precision therapies in development for genetic forms of heart disease. Matt forged strategic partnerships and led efforts to acquire / in-license multiple programs. Earlier at BioMarin, Matt led portfolio strategy initiatives across the entire rare disease and commercial portfolio, developing program and therapeutic area strategies and shaping resource allocation. He also co-led the development and implementation of BioMarin’s new R&D strategy and pivot into more common diseases, resulting in a rapid expansion of the pipeline.

Matt joined Renovacor in conjunction with the company’s IPO to become its first Chief Scientific Officer. He led the R&D organization in developing gene therapies for rare and common cardiovascular diseases, developed the R&D strategic vision, built out the organization, and doubled the pipeline. Renovacor was acquired by Rocket Pharmaceuticals in Dec 2022.

At Biogen, Matt supported the successful launch and commercialization of multiple therapies, and he was previously a management consultant for leading biopharma companies. Matt has a Ph.D. in cardiac electrophysiology from the University of Cambridge and was awarded research fellowships from Massachusetts General Hospital and Harvard Medical School. Matt has been elected a fellow of the Royal Society of Biology, the American College of Cardiology, and the Heart Rhythm Society.